| Targeting CD38 with daratumumab monotherapy in multiple myeloma HM Lokhorst, T Plesner, JP Laubach, H Nahi, P Gimsing, M Hansson, ... New England Journal of Medicine 373 (13), 1207-1219, 2015 | 1279 | 2015 |
| Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group P Sonneveld, H Avet-Loiseau, S Lonial, S Usmani, D Siegel, ... Blood, The Journal of the American Society of Hematology 127 (24), 2955-2962, 2016 | 934 | 2016 |
| Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma J Krejcik, T Casneuf, IS Nijhof, B Verbist, J Bald, T Plesner, K Syed, K Liu, ... Blood, The Journal of the American Society of Hematology 128 (3), 384-394, 2016 | 931 | 2016 |
| Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA … P Moreau, M Attal, C Hulin, B Arnulf, K Belhadj, L Benboubker, MC Béné, ... The Lancet 394 (10192), 29-38, 2019 | 906 | 2019 |
| International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 435 | 2016 |
| CD38 antibodies in multiple myeloma: back to the future NWCJ Van de Donk, PG Richardson, F Malavasi Blood, The Journal of the American Society of Hematology 131 (1), 13-29, 2018 | 423 | 2018 |
| Teclistamab in relapsed or refractory multiple myeloma P Moreau, AL Garfall, NWCJ van de Donk, H Nahi, JF San-Miguel, A Oriol, ... New England Journal of Medicine 387 (6), 495-505, 2022 | 418 | 2022 |
| European Myeloma Network guidelines for the management of multiple myeloma-related complications E Terpos, M Kleber, M Engelhardt, S Zweegman, F Gay, E Kastritis, ... haematologica 100 (10), 1254, 2015 | 404 | 2015 |
| International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders J Hillengass, S Usmani, SV Rajkumar, BGM Durie, MV Mateos, S Lonial, ... The lancet oncology 20 (6), e302-e312, 2019 | 378 | 2019 |
| Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond NWCJ van de Donk, ML Janmaat, T Mutis, JJ Lammerts van Bueren, ... Immunological reviews 270 (1), 95-112, 2016 | 372 | 2016 |
| CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma IS Nijhof, T Casneuf, J Van Velzen, B van Kessel, AE Axel, K Syed, ... Blood, The Journal of the American Society of Hematology 128 (7), 959-970, 2016 | 361 | 2016 |
| Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study SK Kumar, MA Dimopoulos, E Kastritis, E Terpos, H Nahi, H Goldschmidt, ... Leukemia 31 (11), 2443-2448, 2017 | 319 | 2017 |
| CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance NWCJ Van de Donk, SZ Usmani Frontiers in immunology 9, 406716, 2018 | 285 | 2018 |
| Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab IS Nijhof, RWJ Groen, HM Lokhorst, B Van Kessel, AC Bloem, ... Leukemia 29 (10), 2039-2049, 2015 | 282 | 2015 |
| European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma M Engelhardt, E Terpos, M Kleber, F Gay, R Wäsch, G Morgan, M Cavo, ... haematologica 99 (2), 232, 2014 | 273 | 2014 |
| A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization E Drent, M Themeli, R Poels, R de Jong-Korlaar, H Yuan, J de Bruijn, ... Molecular therapy 25 (8), 1946-1958, 2017 | 249 | 2017 |
| Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma NWCJ van de Donk, P Moreau, T Plesner, A Palumbo, F Gay, JP Laubach, ... Blood, The Journal of the American Society of Hematology 127 (6), 681-695, 2016 | 229 | 2016 |
| The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma HM Lokhorst, K Wu, LF Verdonck, LL Laterveer, NWCJ van de Donk, ... blood 103 (11), 4362-4364, 2004 | 207 | 2004 |
| Talquetamab, a T-cell–redirecting GPRC5D bispecific antibody for multiple myeloma A Chari, MC Minnema, JG Berdeja, A Oriol, NWCJ van de Donk, ... New England Journal of Medicine 387 (24), 2232-2244, 2022 | 192 | 2022 |
| Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group P Moreau, SK Kumar, J San Miguel, F Davies, E Zamagni, N Bahlis, ... The Lancet Oncology 22 (3), e105-e118, 2021 | 192 | 2021 |
